
Novel мощный antiangiogenic agent, связывание to VEGFR2, significantly reducing neovascularization in both ex vivo and in vivo angiogenic assays without affecting the proliferation of endothelial cells
Novel potent antiangiogenic agent, binding to VEGFR2, significantly reducing neovascularization in both ex vivo and in vivo angiogenic assays without affecting the proliferation of endothelial cells
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.